Arca
Skip to content
Tools
Tools

Label Changes: Winrevair (sotatercept-csrk)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Winrevair label DailyMed has published, from Merck Sharp & Dohme LLC, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 11
  • Sections changed, version 12 to 13: 10

What changed from version 12 to version 13

Aug 31, 2026 to Oct 8, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged · 5 words added, 8 removed
  2. ContraindicationsChanged · 29 words added, 1 removed
  3. Warnings and precautionsChanged · 187 words added, 98 removed
  4. Adverse reactionsChanged · 488 words added, 210 removed
  5. Use in specific populationsChanged · 27 words added, 56 removed
  6. Clinical pharmacologyChanged · 76 words added
  7. Clinical studiesChanged · 572 words added, 4 removed
  8. How suppliedChanged · 2 words added, 2 removed
  9. Patient counseling informationChanged · 87 words added, 54 removed
  10. Patient informationChanged · 121 words added, 34 removed

Dosage and administration

Changed5 words added, 8 removed
30 unchanged lines
2.3 Dosage Modifications Due to Hemoglobin Increase or Platelet Count Decrease
Check Hgb and platelet count before each dose for the first 5 doses, or longer if values are unstable. Thereafter, monitor Hgb and platelet count periodically [see Warnings and Precautions (5.12, 5.23)].
Delay treatment for at least 3 weeks if any of the following occur:
Hgb increases >2.0 g/dL from the previous dose and is above ULN.
Hgb increases >4.0 g/dL from baseline.
Hgb increases >2.0 g/dL above ULN.
Platelet count decreases to <50,000/mm3 (<50 x 109/L).
1 unchanged line
2.4 Preparation and Administration
Administration is subject to monitoring of hemoglobin and platelet count [see Dosage and Administration (2.3), Warnings and Precautions (5.12, 5.23)].
WINREVAIR is intended for use under the guidance of a healthcare professional. Patients and caregivers may administer WINREVAIR when considered appropriate and when they receive training and follow-up from the healthcare provider (HCP) on how to reconstitute, prepare, measure, and inject WINREVAIR [see Patient Counseling Information (17)].
Confirm at subsequent visits that the patient and/or caregiver can correctly prepare and administer WINREVAIR, particularly if the dose changes or the patient requires a different kit [see Warnings and Precautions (5.12)].
Refer to the Instructions for Use (IFU) for detailed instructions on the proper preparation and administration of WINREVAIR.
21 unchanged lines

Contraindications

Changed29 words added, 1 removed
4 CONTRAINDICATIONS
None.
4.1 Hypersensitivity
WINREVAIR is contraindicated in patients with serious hypersensitivity (i.e., anaphylaxis, angioedema) to sotatercept-csrk or any of its excipients [see Warnings and Precautions (5.1)].

Warnings and precautions

Changed187 words added, 98 removed
5 WARNINGS AND PRECAUTIONS
5.1 Erythrocytosis
5.1 Hypersensitivity
Serious hypersensitivity reactions have been reported in WINREVAIR-treated patients. If a serious hypersensitivity reaction (including anaphylaxis and angioedema) occurs, discontinue WINREVAIR and institute appropriate emergency treatment. Inform patients of the signs and symptoms of hypersensitivity reactions and advise them to seek immediate medical attention if symptoms occur [see Contraindications (4.1) and Adverse Reactions (6.2) ].
5.2 Erythrocytosis
WINREVAIR may increase hemoglobin. Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. In clinical studies, moderate elevations in Hgb (>2 g/dL above ULN) occurred in 15% of patients taking WINREVAIR while no elevations ≥4 g/dL above ULN were observed. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required [see Dosage and Administration (2.3), Adverse Reactions (6.1)].
5.23 Severe Thrombocytopenia
WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. In clinical studies, severe thrombocytopenia (platelet count <50,000/mm3 [<50 x 109/L]) occurred in 3% to 6% of patients taking WINREVAIR. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion.
1 unchanged line
Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required. [see Dosage and Administration (2.3), Adverse Reactions (6.1)].
5.34 Serious Bleeding
In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% vs 1% (STELLAR) and 7% vs 5% (ZENITH) of patients taking WINREVAIR vs placebo, respectively [see Clinical Studies (14.1)]. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Evaluate and treat bleeding accordingly. Do not administer WINREVAIR if the patient is experiencing serious bleeding [see Warnings and Precautions (5.2), Adverse Reactions (6.1)].
WINREVAIR increases the risk of bleeding. In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% vs 1% (STELLAR), 7% vs 5% (ZENITH), and 4% vs 2% (HYPERION) of patients taking WINREVAIR vs placebo, respectively [see Clinical Studies (14.1), Adverse Reactions (6.1)].
Post-marketing cases of gastrointestinal bleeding associated with angiodysplasias have been reported in WINREVAIR-treated patients; endoscopic evaluation should be considered in patients with recurrent or unexplained gastrointestinal bleeding [see Adverse Reactions (6.1 and 6.2)].
Advise patients about signs and symptoms of blood loss. Evaluate and treat bleeding accordingly. Do not administer WINREVAIR if the patient is experiencing serious bleeding [see Warnings and Precautions (5.3), Adverse Reactions (6.1)].
5.45 Embryo-Fetal Toxicity
Based on findings in animal reproduction studies, WINREVAIR may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of WINREVAIR to pregnant rats and rabbits during organogenesis resulted in adverse developmental outcomes, including increased embryo-fetal mortality, alterations to growth, and structural variations at exposures 4-fold and 0.6-fold (based on area under the curve [AUC]) those occurring at the maximum recommended human dose (MRHD), respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose [see Use in Specific Populations (8.1, 8.3)].
5.56 Impaired Fertility
Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

Adverse reactions

Changed488 words added, 210 removed
1 unchanged line
The following clinically significant adverse reactions are described elsewhere in the labeling:
ErythrocytosisHypersensitivity [see Warnings and Precautions (5.1)]
Severe ThrombocytopeniaErythrocytosis [see Warnings and Precautions (5.2)]
SeriousSevere BleedingThrombocytopenia [see Warnings and Precautions (5.3)]
Embryo-FetalSerious ToxicityBleeding [see Warnings and Precautions (5.4)]
ImpairedEmbryo-Fetal FertilityToxicity [see Warnings and Precautions (5.5)]
Impaired Fertility [see Warnings and Precautions (5.6)]
6.1 Clinical Trials Experience
25 unchanged lines
The overall incidences of adverse reactions in both arms were higher in the ZENITH trial than in the STELLAR trial. Severe reduction in platelet count <50,000/mm3 (<50.0 x 109/L) occurred in 6% of patients taking WINREVAIR. In the WINREVAIR group, 1 patient (1%) discontinued study intervention due to an adverse event, compared with 4 patients (5%) in the placebo group.
The most common adverse reactions occurring in ZENITH (≥10% for WINREVAIR and at least 5% more than placebo) are shown in Table 4.
Table 4: Adverse Reactions ≥10% in Patients Receiving WINREVAIR and at least 5% More Than Placebo in ZENITH
5 unchanged lines
Increased hemoglobin | 13 (15.1) | 1 (1.2)
Gastrointestinal tract bleeding | 10 (11.6) | 0 (0.0)
Rash | 9 (10.5) | 4 (4.7)
1 unchanged line
Gingival bleeding | 9 (10.5) | 2 (2.3)
HYPERION
The following data reflect exposure to WINREVAIR in the HYPERION trial. Newly diagnosed adult PAH patients in WHO FC II or III at intermediate or high risk of disease progression (n=320) were randomized in a 1:1 ratio to treatment with WINREVAIR or placebo in combination with background standard of care therapies. The median duration of exposure was longer in the WINREVAIR group (443 days) than in the placebo group (350 days) [see Clinical Studies (14.1)].
The adverse reactions observed in the HYPERION trial were generally consistent with those observed in the STELLAR trial. No severe reductions in platelet count <50,000/mm3 (<50.0 x 109/L) occurred in the WINREVAIR group. Treatment discontinuation due to an adverse event occurred in 3% (epistaxis was the most common reason) and 0% of the WINREVAIR and placebo groups, respectively.
The most common adverse reactions occurring in HYPERION (≥10% for WINREVAIR and at least 5% more than placebo) are shown in Table 5.
Table 5: Adverse Reactions ≥10% in Patients Receiving WINREVAIR and at least 5% More Than Placebo in HYPERION
Adverse reaction | WINREVAIR N=160 | Placebo N=160
Epistaxis | 51 (31.9) | 11 (6.9)
Telangiectasia | 42 (26.3) | 18 (11.3)
Increased hemoglobin | 18 (11.3) | 2 (1.3)
Additional Controlled Safety Data from Clinical Trials
Gastrointestinal disorders: In a pooled analysis of STELLAR, ZENITH, and HYPERION, gastrointestinal bleeding was observed in 7% of patients in the sotatercept group compared with 2% in the placebo group. Colonic angioectasia was reported in 2% of patients in the sotatercept group compared with 0.2% in the placebo group.
Uncontrolled Long-term Safety Data
Pooled long-term safety data are available from 431 patients who participated in multicenter phase 2 (PULSAR, SPECTRA) and phase 3 (STELLAR) clinical trials. A majority of these patients continued in SOTERIA, an ongoing, open-label follow-up study of the long-term safety and efficacy of WINREVAIR.
Pooled long-term safety data are available from 431 patients who participated in multicenter phase 2 (PULSAR, SPECTRA) and phase 3 (STELLAR) clinical trials. A majority of these patients continued in SOTERIA, an ongoing, open-label follow-up study of the long-term safety and efficacy of WINREVAIR. The safety profile with long-term exposure was generally similar to that observed in the STELLAR study. The mean duration of exposure to WINREVAIR was 173 weeks with a maximum exposure of 335 weeks.
The safety profile with long-term exposure was generally similar to that observed in the STELLAR study. The mean duration of exposure to WINREVAIR was 173 weeks with a maximum exposure of 335 weeks.
Skin hypopigmentation: In the pooled long-term safety population (n=431), skin hypopigmentation was reported in 5% of patients. Reported manifestations included white or hypochromic spots and hypopigmented macules affecting the extremities or trunk. No events required dose reduction or treatment interruption.
Intrapulmonary Right-to-Left Shunting: Cases of intrapulmonary right-to-left shunting have been reported in a clinical trial with WINREVAIR.: In SOTERIA, right-to-left intrapulmonary shunting has been reported in 3 participants (<0.7%) who developed worsening hypoxemia despite improved PAH hemodynamics. Post-marketing cases have also been reported. Partial to complete improvement in oxygenation has been observed following discontinuation of WINREVAIR.
Partial to complete improvement in oxygenation has been observed following discontinuation of WINREVAIR.
Additional Adverse Reactions from Clinical Trials
The following adverse reactions were reported in at least one adult patient receiving treatment with WINREVAIR. These adverse reactions are presented by system organ class and are ranked by frequency.
Skin and Subcutaneous Tissue Disorders: 1% and less than 10%: skin hypopigmentation
Gastrointestinal Disorders: 1% and less than 10%: gastrointestinal tract bleeding (including gastrointestinal hemorrhage, upper gastrointestinal hemorrhage, hematemesis, lower gastrointestinal hemorrhage, hematochezia, rectal hemorrhage, melaena, gastritis hemorrhagic), colonic angioectasia
6.2 Post-marketing Experience
The following adverse reaction has been reported during post-approval use of WINREVAIR. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac disorders: pericardial effusion General disorders and administration site conditions: injection site reactions
Cardiac disorders: pericardial effusion Gastrointestinal disorders: gastrointestinal hemorrhage, gastrointestinal angiodysplasia General disorders and administration site conditions: injection site reactions Immune disorders: hypersensitivity reactions (including anaphylaxis and angioedema) [see Warnings and Precautions (5.1)]

Use in specific populations

Changed27 words added, 56 removed
28 unchanged lines
8.5 Geriatric Use
A total of 127257 patients ≥65 years of age participated in clinical studies for PAH, of which 99167 (7865%) were treated with WINREVAIR. No differences in efficacy of WINREVAIR were observed between the <65-year-old and ≥65-year-old subgroups.
With the exception of bleeding events (a collective group of adverse events of clinical interest), there were no differences in safety between the <65-year-old and ≥65-year-old subgroups. Bleeding events occurred more commonly in the older WINREVAIR subgroup, but with no imbalance between age subgroups for any specific bleeding event.
Bleeding events occurred more commonly in patients ≥65 years of age, with a greater imbalance in gastrointestinal bleeding events [see Adverse Reactions (6.1) ].
Clinical studies of WINREVAIR did not include sufficient numbers of patients aged 75 and older to determine whether they respond differently from younger patients.

Clinical pharmacology

Changed76 words added
7 unchanged lines
The median treatment difference in change in PVR from baseline between the sotatercept and placebo groups after 24 weeks was -340 dynes*sec/cm5 (95% CI: -511, -168). The median treatment difference in change in NT-proBNP from baseline between the sotatercept-csrk and placebo groups after 24 weeks was -2339 pg/mL (95% CI: -3379, -1299). The median treatment difference in change from baseline in mean pulmonary artery pressure (mPAP) between the sotatercept-csrk and placebo groups after 24 weeks was -21.2 mm Hg (95% CI: -27.8, -14.6).
HYPERION
The median treatment difference in change in NT-proBNP from baseline between the sotatercept and placebo groups after 24 weeks was -308.6 pg/mL (95% CI: -434.84, -182.37) [See Clinical Studies (14.1)].
12.3 Pharmacokinetics
Following subcutaneous administration of 0.7 mg/kg WINREVAIR every three weeks to PAH patients (PULSAR, SPECTRA, and STELLAR), the steady state geometric mean (%CV) area under the time concentration curve (AUC) is 171.3 mcg×d/mL (34.2%), and peak concentration (Cmax) is 9.7 mcg/mL (30%). Sotatercept-csrk AUC and Cmax increased proportionally with dose. Steady state is achieved after approximately 15 weeks following initiation of multiple dosing. The accumulation ratio of sotatercept-csrk AUC is approximately 2.2. Sotatercept-csrk pharmacokinetics were similar in PAH participants in phase 3 studies, ZENITH and HYPERION.
Absorption
14 unchanged lines
During the ZENITH trial, with a median sotatercept treatment duration of 435 days, 43% (36/84) of patients developed anti-sotatercept antibodies. Among these 36 patients, 20 (56%) tested positive for neutralizing antibodies against sotatercept.
During the HYPERION trial with a median sotatercept treatment duration of 443 days, 63/159 (40%) patients developed anti-sotatercept antibodies. Among these 63 patients, 25 (40%) tested positive for neutralizing antibodies against sotatercept.
There were no identified clinical effects of anti-sotatercept-csrk antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of sotatercept-csrk over the treatment duration of 24 weeks at the recommended dosage in these studies.

Clinical studies

Changed572 words added, 4 removed
3 unchanged lines
The efficacy of WINREVAIR was evaluated in adult patients with PAH in the STELLAR trial (NCT04576988). STELLAR was a global, double-blind, placebo-controlled, multicenter, parallel-group clinical trial in which 323 patients with PAH (WHO Group 1, FC II or III) were randomized 1:1 to WINREVAIR (target dose 0.7 mg/kg) (n=163) or placebo (n=160) administered subcutaneously once every 3 weeks.
Participants were: 79% female; had a median age of 48 years (range: 18 to 82 years), and median body weight of 68 kg (range: 38 to 141 kg); and 89% White, 2% Black/African American, 2% Asian, 0.3% American Indian or Alaska Native, 0.3% Native Hawaiian or Other Pacific Islander, 6% Missing/Other races. The most common PAH etiologies were idiopathic PAH (59%), heritable PAH (18%), and PAH associated with connective tissue diseases (CTD) (15%). STELLAR excluded patients with human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, and pulmonary veno -occlusive disease. The mean time from PAH diagnosis to screening was 8.8 years. Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. Patients had a WHO FC II (49%) or III (51%) at baseline.
The primary efficacy endpoint was the change from baseline at Week 24 in 6-Minute Walk Distance (6 MWD). In the WINREVAIR group, the placebo-adjusted median increase in 6 MWD was 41 meters (95% CI: 28, 54; p<0.001). Figure 1 displays placebo-adjusted changes in 6 MWD at Week 24 in relevant subgroups.
2 unchanged lines
Treatment with WINREVAIR led to an improvement from baseline by at least 1 WHO FC at Week 24 in 29% of patients compared to 14% of patients treated with placebo (p<0.001).
Treatment with WINREVAIR resulted in an 84% reduction in the occurrence of death from any cause or PAH clinical worsening events compared to placebo (see Table 56 and Figure 2). These outcomes were captured until the last patient completed the Week 24 visit (data up to the data cutoff; median duration of exposure 33.6 weeks).
Table 56: Death from Any Cause or PAH Clinical Worsening Events in STELLAR
| WINREVAIR (N=163) n (%) | Placebo (N=160) n (%) | Hazard Ratio (95% CI)
12 unchanged lines
The demographic and baseline clinical characteristics were similar between the WINREVAIR and placebo groups. Participants were: 77% female; had a median age of 58 years (range: 18 to 75 years); and 87% White, 5% Black/African American, 4% Asian, 1% American Indian or Alaska Native, 3% Missing/Other race, 74% were FC III and 26% were FC IV. The most common PAH etiologies were idiopathic PAH (50%), PAH associated with connective tissue diseases (CTD) (28%), and heritable PAH (11%). The mean time since PAH diagnosis to screening was 8 years. Participants were on background PAH treatment, 72% on triple therapy, 28% on double therapy, and 59% on prostacyclin infusion therapy. The REVEAL Lite 2 risk score was <9 for 2% of participants, 9 to 10 for 67% of participants, and ≥11 for 30% of participants. The ZENITH trial excluded patients diagnosed with human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis or overt signs of capillary and/or venous involvement.
The primary efficacy endpoint was time to first event of all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours. In the WINREVAIR treatment group, the risk of a first event of all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours was 76% lower compared with the placebo group (HR: 0.24; 95% CI: 0.13, 0.43; p<0.0001) (see Table 67 and Figure 3). Fewer participants in the WINREVAIR group (15 [17%]) than in the placebo group (47 [55%]) had a primary endpoint event as of the data cutoff. Based on the primary endpoint result, the study was stopped for favorable efficacy at the interim analysis.
The treatment effect of WINREVAIR was consistent across the prespecified subgroups (see Figure 4).
Table 67: Primary Endpoint Results in ZENITH
| WINREVAIR (N=86) n (%) | Placebo (N=86) n (%) | Hazard Ratio (95% CI) p-value
9 unchanged lines
Subsequent secondary endpoints were not eligible to be tested due to the hierarchical testing strategy.
HYPERION
The efficacy of WINREVAIR was evaluated in adults with newly diagnosed PAH (WHO FC II or III, diagnosis within 12 months of study screening) at intermediate to high risk of disease progression in the HYPERION trial (NCT04811092). HYPERION was a global, double-blind, placebo-controlled clinical trial in which 320 patients were randomized 1:1 to WINREVAIR (target dose 0.7 mg/kg) (n=160) or placebo (n=160) administered subcutaneously once every 3 weeks. HYPERION was stopped early based on the positive results from the pre-specified interim analysis of the ZENITH trial and a review of the totality of data from the WINREVAIR clinical program.
The demographic and baseline clinical characteristics were similar between the WINREVAIR and placebo groups. Participants were 73% female, had a median age of 60 years (range: 18 to 88 years), 21% were FC II and 79% were FC III. The most common PAH etiologies were idiopathic PAH (59%) and PAH associated with connective tissue diseases (CTD) (30%). The mean time since PAH diagnosis was 7.2 months (range: 0.1 to 14.5 months). Participants were on background PAH treatment, with 72% on double therapy, 28% on triple therapy, and 17% on prostacyclin infusion therapy. REVEAL Lite 2 risk scores were <6 in 21%, 6-7 in 51%, and ≥8 in 28% of participants, respectively. COMPERA 2 risk scores were low in 2%, intermediate-low in 64%, intermediate-high in 32%, high in 2%, and missing in 0.3% of participants, respectively.
The primary efficacy endpoint was time to clinical worsening (TTCW), defined as the time to death or the first confirmed morbidity event (Table 8). HYPERION was stopped early prior to reaching the pre-specified number of events for the final analysis (121 events planned, 76 events observed). In the WINREVAIR treatment group, the risk of experiencing a first clinical worsening event was 76% lower compared with the placebo group (HR: 0.24; 95% CI: 0.14, 0.41; p<0.0001) (see Table 8). The treatment effect of WINREVAIR was consistent across the prespecified subgroups: age, sex, PAH subtype (idiopathic PAH, CTD-associated PAH), double versus triple background PAH therapy, WHO FC, prostacyclin infusion versus non prostacyclin infusion therapy, PVR, eGFR, REVEAL Lite 2 score, intermediate-low versus intermediate-high COMPERA 2 risk score.
Table 8: Primary Endpoint Results in HYPERION
| WINREVAIR (N=160) n (%) | Placebo (N=160) n (%) | Hazard Ratio (95% CI) p-value
Number of participants with: at least 1 primary event | 17 (10.6) | 59 (36.9) | 0.24 (0.14, 0.41) <0.0001
Components of primary endpoint |
All-cause death | 7 (4.4) | 6 (3.8)
Non-planned PAH-related hospitalization of ≥24 hours | 3 (1.9) | 14 (8.8)
Atrial septostomy | 0 | 0
Lung transplantation | 0 | 0
Deterioration in performance due to PAH | 8 (5.0) | 46 (28.8)
The first secondary endpoint, multicomponent improvement (MCI) was measured by the proportion of participants achieving all of the following at Week 24 relative to baseline: improvement in 6MWD (increase ≥30 m), improvement in NT-proBNP (decrease in NT-proBNP ≥30% or maintenance/achievement of NT-proBNP level <300 ng/L), and improvement in WHO FC or maintenance of WHO FC II. The proportion of participants who met all three MCI criteria was significantly greater in the WINREVAIR group (29.4%) than in the placebo group (14.6%) (p=0.003).

How supplied

Changed2 words added, 2 removed
1 unchanged line
16.1 How Supplied
WINREVAIR (sotatercept-csrk) for injection is a white to off-white lyophilized cake or powder appearance supplied in single-dose vials (45 mg or 60 mg) packaged in kits that contain one measuring syringe and one safety needle. Each kit also contains Sterile Water for Injection in prefilled syringes necessary to reconstitute the product, vial adapter(s), and alcohol pads, as shown in Table 79.
Table 79: Kit Contents
Kit | Vial Adapters | Alcohol Pads | Sterile Water for Injection in prefilled syringes | NDC
7 unchanged lines

Patient counseling information

Changed87 words added, 54 removed
2 unchanged lines
Discuss the following with patients prior to and during treatment with WINREVAIR.
Hypersensitivity
Advise patients that serious allergic reactions, including anaphylaxis and angioedema, have been reported with WINREVAIR. Instruct patients to seek immediate medical attention if they experience signs or symptoms of a serious allergic reaction, such as hives; swelling of the face, lips, tongue, or throat; or difficulty breathing or swallowing [see Warnings and Precautions (5.1)].
Erythrocytosis
Caution patients that WINREVAIR may raise Hgb to levels that increase their risk of thrombotic events. Inform patients that Hgb levels will be assessed before at least the first 5 doses and then periodically, as dosage may need to be adjusted [see Warnings and Precautions (5.12)].
Severe Thrombocytopenia
Caution patients that WINREVAIR may cause platelet count to decrease, which if severe could cause bleeding. Inform patients that platelet count will be assessed before at least the first 5 doses and then periodically, as dosage may need to be adjusted [see Warnings and Precautions (5.23)].
Serious Bleeding
Inform patients of the possibility of serious bleeding, which is more likely to occur if they have low platelet counts or while on prostacyclin background therapy and/or antithrombotic agents. Advise patients to notify their healthcare provider about signs and symptoms of bleeding [see Warnings and Precautions (5.3)].
Inform patients of the possibility of serious bleeding. Advise patients to notify their healthcare provider about signs and symptoms of bleeding [see Warnings and Precautions (5.4)].
Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception while receiving WINREVAIR and for at least 4 months after the final dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected during treatment with WINREVAIR [see Warnings and Precautions (5.45), Use in Specific Populations (8.1)]. Report exposure during pregnancy or lactation to the Merck Sharp & Dohme, LLC Adverse Event reporting line at 1-877-888-4231.
Lactation
15 unchanged lines
For patent information: www.msd.com/research/patent
Copyright © 2024-2026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
uspi-mk7962-i-2608r0062609r007

Patient information

Changed121 words added, 34 removed
This Patient Information has been approved by the U.S. Food and Drug Administration | Revised: OctoberSeptember 20252026
PATIENT INFORMATION WINREVAIR™ (WIN-reh-vair) (sotatercept-csrk) for injection, for subcutaneous use
What is WINREVAIR? WINREVAIR is a prescription medicine used to treat adults with pulmonary arterial hypertension (PAH). PAH is a type of high blood pressure in the arteries of your lungs. WINREVAIR can: improve your ability to exercise and perform normal activities with fewer symptoms, and reduce the risk of your physical condition and symptoms worsening, including lowering your risk of hospitalization for PAH, lung transplant, and death. It is not known if WINREVAIR is safe and effective in children under 18 years of age.
Who should not take WINREVAIR? Do not take WINREVAIR if you have had a serious allergic reaction to sotatercept-csrk or any of the other ingredients in WINREVAIR. See the end of this Patient Information leaflet for a complete list of ingredients in WINREVAIR.
What should I tell my healthcare provider before taking WINREVAIR? Tell your healthcare provider about: All of your medical conditions All of the medicines you take, including prescriptions and over-the-counter medicines, vitamins, or herbal supplements If you are able to get pregnant: WINREVAIR may harm your unborn baby. Tell your healthcare provider if you are pregnant or planning to get pregnant. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with WINREVAIR. Your healthcare provider should do a pregnancy test before you start taking WINREVAIR. You should use effective birth control during treatment with WINREVAIR and for at least 4 months after your final dose. Ask your healthcare provider about birth control methods that may be right for you. You or your healthcare provider should report any exposure to WINREVAIR during pregnancy by calling 1-877-888-4231. If you are breastfeeding or planning to breastfeed: Tell your healthcare provider if you are breastfeeding or planning to breastfeed. It is not known if WINREVAIR passes into breast milk. Do not breastfeed during treatment with WINREVAIR and for 4 months after your final dose. Talk to your healthcare provider about the best way to feed your baby. You or your healthcare provider should report any exposure to WINREVAIR during breastfeeding by calling 1-877-888-4231.
Before you take WINREVAIR: If your healthcare provider decides that you or a caregiver can give your injections of WINREVAIR at home, you or your caregiver should receive training from your healthcare provider on the right way to prepare and inject WINREVAIR. Do not try to inject WINREVAIR until you have been shown how to inject WINREVAIR by your healthcare provider. Your healthcare provider will do a blood test before your first 5 doses of WINREVAIR, longer if needed, and then from time to time to check your levels of hemoglobin (a protein in red blood cells that carries oxygen) and platelets (blood cells that help blood clot). After each of these blood tests, your healthcare provider may delay treatment or change your dose if needed. See the detailed “Instructions for Use” booklet that comes with WINREVAIR for information on how to prepare and inject a dose of WINREVAIR. How should I take WINREVAIR? Use WINREVAIR exactly as your healthcare provider tells you to. You will give WINREVAIR every 3 weeks as an injection just under your skin (subcutaneous) in your: stomach (abdomen) at least 2 inches away from the belly button, or upper thigh You should inject WINREVAIR right away after mixing the medicine powder with the sterile water for injection, but no later than 4 hours after mixing. Your prescribed dose: Your healthcare provider will tell you how much WINREVAIR to inject and when to inject it. This is because your prescribed dose depends on your body weight and blood tests. Do not change your dose or stop taking WINREVAIR without talking to your healthcare provider. Do not take WINREVAIR more often than your healthcare provider tells you to. If you are not sure when to take WINREVAIR, call your healthcare provider. Your healthcare provider may delay treatment, change your dose, or stop treatment depending on how you respond to WINREVAIR. What if I take the wrong dose or miss my dose? If you give more than or less than your prescribed dose, call your healthcare provider right away. If you miss your dose of WINREVAIR: If it has been 3 days or fewer, give it as soon as possible. You can then follow your usual schedule for your next dose. If it has been more than 3 days, call your healthcare provider for what to do.
What are the possible side effects of WINREVAIR? WINREVAIR may cause serious side effects including: Allergic (hypersensitivity) reactions. Allergic reactions, including anaphylaxis, can happen within hours or days after you use WINREVAIR. Call your healthcare provider or get medical help right away if you have any of these symptoms: hives swelling of your face, lips, tongue or throat sudden trouble breathing or swallowing Before your next dose of WINREVAIR, tell your healthcare provider if you have had any symptoms of an allergic reaction. High level of hemoglobin in your blood. High levels of hemoglobin are common with WINREVAIR and can be severe and increase your risk for blood clots. Your healthcare provider will do blood tests to check your hemoglobin levels before starting and regularly during treatment with WINREVAIR. Severely low number of platelets in your blood. Low platelet counts are common with WINREVAIR and can be severe and increase your risk of bleeding. Your healthcare provider will do blood tests to check your platelet levels before starting and regularly during treatment with WINREVAIR. Tell your healthcare provider if you develop easy bruising or bleeding, bleeding that does not stop, or nosebleeds. Serious bleeding. You are more likely to have seriousSerious bleeding if you have low platelet counts, take prostacyclin medicines to treat PAH, or take medicines to help keep bloodcan clotshappen fromwith formingWINREVAIR. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:
| vomiting blood or your vomit looks like coffee-grounds pink or brown urine red or black stools that look like tar coughing up blood or blood clots persistent headaches | nausea dizziness or feeling weak persistent abdominal cramps severe back pain abnormally heavy menstrual bleeding
7 unchanged lines
What are the ingredients in WINREVAIR? Active ingredient: sotatercept-csrk Inactive ingredient(s): citric acid monohydrate, polysorbate 80, sodium citrate, and sucrose.
Manufactured by: Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA. US License Number 0002 For patent information: www.msd.com/research/patent Copyright © 2024-20252026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. usppi-mk7962-i-2510r0012609r002 For more information, call 1-877-888-4231, or go to www.WINREVAIR.com .

Unchanged: Indications and usage, Dosage forms and strengths, Overdosage, Description, Nonclinical toxicology, Instructions for use, PRINCIPAL DISPLAY PANEL - 45 mg Vial Kit Carton, PRINCIPAL DISPLAY PANEL - 60 mg Vial Kit Carton, PRINCIPAL DISPLAY PANEL - 45 mg 2 Vials Kit Carton, PRINCIPAL DISPLAY PANEL - 60 mg 2 Vials Kit Carton.

Every version

11 versions of set 21693ee2-cd23-4137-ac67-066bb3a4a9b7, newest first.
VersionPublished on DailyMedCompareSPL file
13Oct 8, 2026Shown belowDownload .zip
12Aug 31, 2026With version 11Download .zip
11Jul 29, 2026With version 10Download .zip
10Jul 7, 2026With version 9Download .zip
9Jun 23, 2026With version 8Download .zip
8Mar 24, 2026With version 7Download .zip
7Jan 5, 2026With version 6Download .zip
6Nov 17, 2025With version 5Download .zip
5Sep 29, 2025With version 4Download .zip
4May 7, 2025With version 2Download .zip
2Apr 5, 2024First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.